Literature DB >> 11863229

Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases.

Renato Tozzoli1, Nicola Bizzaro, Elio Tonutti, Danilo Villalta, Danila Bassetti, Fabio Manoni, Anna Piazza, Marco Pradella, Paolo Rizzotti.   

Abstract

The Italian Society of Laboratory Medicine Study Group on the Diagnosis of Autoimmune Diseases has generated a series of guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intendedfor the use of clinical pathologists and laboratory physicians. These guidelines are based on a systematic review of published works and expert panel discussion and consist of 13 recommendations for antinuclear antibodies, anti-double-stranded native DNA, and antinuclear specific antibodies. To improve analytic performances and help select the most appropriate test for specific autoantibodies, as well as provide education and guidance in the use of these tests, special emphasis is placed on laboratory methods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863229     DOI: 10.1309/Y5VF-C3DM-L8XV-U053

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  43 in total

1.  Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory.

Authors:  J Kwok; B Jones
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 2.  Serologic testing in connective tissue diseases.

Authors:  Dana E Habash-Bseiso; Steven H Yale; Ingrid Glurich; Jerry W Goldberg
Journal:  Clin Med Res       Date:  2005-08

3.  A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases.

Authors:  Nicola Bizzaro; Gabriella Morozzi
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

4.  A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies.

Authors:  O Shovman; N Agmon-Levin; B Gilburd; T Martins; A Petzold; T Matthias; Y Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 5.  Autoimmune diagnostics: the technology, the strategy and the clinical governance.

Authors:  Nicola Bizzaro; Renato Tozzoli; Danilo Villalta
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

6.  New automated indirect immunofluorescent antinuclear antibody testing compares well with established manual immunofluorescent screening and titration for antinuclear antibody on HEp-2 cells.

Authors:  M Daves; J Blecken; T Matthias; A Frey; V Perkmann; A Dall Acqua; A Joos; S Platzgummer
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

7.  Antinuclear antibodies detection: A comparative study between automated recognition and conventional visual interpretation.

Authors:  ZhiYan Li; RuiLin Han; ZhenLin Yan; LiJuan Li; ZhenRu Feng
Journal:  J Clin Lab Anal       Date:  2018-07-20       Impact factor: 2.352

8.  An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing.

Authors:  Ada Man; Kam Shojania; Carmen Phoon; Jason Pal; Monika Hudoba de Badyn; David Pi; Diane Lacaille
Journal:  Clin Rheumatol       Date:  2013-01-06       Impact factor: 2.980

9.  Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.

Authors:  Jinoos Yazdany; Gabriela Schmajuk; Mark Robbins; David Daikh; Ashley Beall; Edward Yelin; Jennifer Barton; Adam Carlson; Mary Margaretten; Joann Zell; Lianne S Gensler; Victoria Kelly; Kenneth Saag; Charles King
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

10.  Clinical evaluation of cobas core anti-dsDNA EIA quant.

Authors:  Concepción González; Paloma Guevara; Belén García-Berrocal; José Alejandro Navajo; José Manuel González-Buitrago
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.